Valuation implications of pharmaceutical companies' R&D regulatory approval notifications

Article English OPEN
Hamill, P.A. ; McIlkenny, P. ; Opong, K.K. (2013)

This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges. Applications to the FDA for drug approvals significantly increase shareholder wealth for NYSE firms only. The increase is driven by applications for enhancements to existing drugs, with the market anticipating the application, thus suggesting information leakage. FDA approvals also significantly increase shareholder wealth in both markets. However, there is no evidence of information leakage and the significant post-event abnormal returns support the attention-grabbing hypothesis. Enhanced drug approvals are value-relevant for both markets, which highlights the contribution of real-options to firm value.
  • References (34)
    34 references, page 1 of 4

    Akerlof, G. A. (1970). The market for "lemons": quality uncertainty and the market mechanism, The Quarterly Journal of Economics, 84(3), 488-500.

    Amir, E., & Lev, B. (1996). The value-relevance of nonfinancial information: a discussion.

    Journal of Accounting and Economics, 22, 1-3, 31-42 Botosan, C., & Plumlee, M. (2001). Estimating expected cost of equity capital: a theorybased approach. Working paper, University of Utah, November. Available at SSRN:

    Brown, S.J., & Warner, J.B. (1985). Using Daily Stock Returns, Journal of Financial Economics, 14, 3-31.

    Busby, J.S. & Pitts, C.G., (1997). Real options in practice: an explanatory survey of how finance officers deal with flexibility in capital appraisal. Management Accounting Research, 8, 169-184.

    Corrado, C. J. (1989). A nonparametric test for abnormal security-price performance in event studies. Journal of Financial Economics, 23, 385-395.

    Dedman, E., Lin, W.J., Prakash, A.J., & Chang, C.H. (2008). Voluntary disclosure and its impact on share prices: evidence from the UK biotechnology sector, Journal of Accounting and Public Policy, 27(3), 195-216.

    DiMasi, J. (1995). Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics, 58, 1-14.

    DiMasi, J., Hansen, R., & Grabowski, H. (2003). The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22, 151-185.

    Dranove, D. & Olsen, C. (1994). The economic side effect of dangerous drug announcements, Journal of Law and Economics, 37, 323-348.

  • Metrics
    No metrics available
Share - Bookmark